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Abstract
Treatment options for autosomal dominant polycystic kidney disease (ADPKD) will likely become available in the near
future, hence reliable diagnostic and prognostic biomarkers for the disease are strongly needed. Here, we aimed to define
urinary proteomic patterns in ADPKD patients, which aid diagnosis and risk stratification. By capillary electrophoresis online
coupled to mass spectrometry (CE-MS), we compared the urinary peptidome of 41 ADPKD patients to 189 healthy controls
and identified 657 peptides with significantly altered excretion, of which 209 could be sequenced using tandem mass
spectrometry. A support-vector-machine based diagnostic biomarker model based on the 142 most consistent peptide
markers achieved a diagnostic sensitivity of 84.5% and specificity of 94.2% in an independent validation cohort, consisting
of 251 ADPKD patients from five different centers and 86 healthy controls. The proteomic alterations in ADPKD included,
but were not limited to markers previously associated with acute kidney injury (AKI). The diagnostic biomarker model was
highly specific for ADPKD when tested in a cohort consisting of 481 patients with a variety of renal and extrarenal diseases,
including AKI. Similar to ultrasound, sensitivity and specificity of the diagnostic score depended on patient age and
genotype. We were furthermore able to identify biomarkers for disease severity and progression. A proteomic severity score
was developed to predict height adjusted total kidney volume (htTKV) based on proteomic analysis of 134 ADPKD patients
and showed a correlation of r = 0.415 (p,0.0001) with htTKV in an independent validation cohort consisting of 158 ADPKD
patients. In conclusion, the performance of peptidomic biomarker scores is superior to any other biochemical markers of
ADPKD and the proteomic biomarker patterns are a promising tool for prognostic evaluation of ADPKD.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most frequent hereditary kidney disease, affecting between 1 in
400 and 1 in 1000 individuals of the general population [1,2]. The
growth of innumerable cysts in both kidneys causes progressive
kidney dysfunction leading to end stage renal disease (ESRD) by
the sixth decade in 50% of affected patients [3]. The disease is
caused by mutations in the PKD1 (85% of cases) or the PKD2
gene (15% of cases).
The disease course of ADPKD is characterized by high inter-
and intra-familial variability that hampers the prediction of disease
progression [4]. Affected individuals may retain adequate renal
function until their 9th decade, whereas others progress to ESRD
by their 3rd decade. Genetic modifiers as well as environmental
factors are likely to influence the disease course, although
information on these factors is sparse and the currently known
factors only account for a small proportion of the predictive power
for prognosis [5,6,7]. In particular, glomerular filtration rate
(GFR) remains stable for many decades in the early disease stages,
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when predicting disease progression would be most valuable for
counseling ADPKD patients [8]. During the last decade, several
pathways involved in the generation and growth of cysts in
ADPKD have been unraveled and several of these pathways have
led to the development of targeted medical therapies [9]. Specific
treatment options, such as the vasopressin antagonist tolvaptan,
somatostatin analogues, and angiotensin converting enzyme
inhibitors or angiotensin receptor blockers are currently being
evaluated in large clinical trials that await completion or
publication and may become available in the near future, whereas
other therapeutic options, such as the cyclin dependent kinase
inhibitor roscovitine, are in preclinical development. Since these
treatments will most likely need to be given over long periods of
time, prognostic evaluation of patients will gain further impor-
tance, particularly since the potential therapeutic benefits need to
be balanced against side effects and costs.
The diagnosis of ADPKD is usually based on the observation of
kidney cysts by ultrasound in patients with positive family history
for ADPKD [10]. However, ultrasound imaging has limited
sensitivity in children and young adults, particularly those with
PKD2 mutations, and thus ADPKD cannot be reliably excluded
by ultrasound before the age of 30 years [10]. Furthermore
molecular diagnosis by genetic testing has been hampered by the
genetic complexity of ADPKD, and only 65% of ADPKD patients
exhibit definitive pathogenic (i.e. truncating) mutations [11].
Proteomic analysis of urine offers a noninvasive means to
simultaneously detect changes in the expression and processing of
multiple proteins [12]. In contrast to other body fluids, such as
serum or plasma, the urinary proteome does not undergo
detectable degradation by endogenous proteases after voiding,
thus minimizing the bias introduced by preanalytical sample
handling [13]. CE-MS analysis of over 10,000 individual urine
samples demonstrated high stability and consistency of the urinary
low molecular weight proteome [14]. Through the simultaneous
measurement of hundreds of polypeptides followed by appropriate
statistical analysis, a combination of distinct biomarkers in a
classifier, rather than single biomarkers, can be developed, which
largely increases sensitivity and specificity in comparison to the
singla markers. Urinary biomarkers and biomarker-based classi-
fiers could be validated in several independent studies [15,16,17],
further supporting the validity of the approach and demonstrating
the stability of the human urinary proteome/peptidome.
We have previously identified a urinary polypeptide pattern
characteristic of ADPKD using capillary electrophoresis coupled
online to mass spectrometry (CE-MS) [18]. Here, we sought to
validate these findings in the large prospective ADPKD cohort of
the Consortium for Radiologic Imaging Studies in Polycystic
Kidney Disease (CRISP) and to develop a biomarker model for
disease severity that may aid prognostic evaluation.
Results
The design of the study, samples used and the flow of the data
are graphically depicted in Figure 1. In total, spot urine samples
from 224 CRISP patients [19], 68 patients of the SUISSE
ADPKD study [20],275 healthy controls (mean age 37615 years,
49% females, all caucasians) and from 481 patients suffering from
a variety of non-cystic renal and systemic diseases were analyzed.
The demographic data, kidney volume, GFR and clinical
characteristics were similar among patients of the CRISP and
SUISSE ADPKD cohorts (Table 1). The mean available follow-
up time after collection of urine for proteomic analysis was
2.9960.46 (range: 0.98–4.23) years in the CRISP cohort and
2.1860.49 (range: 1.46–3.37) years in the SUISSE ADPKD
cohort.
Since the previously published biomarker model for ADPKD
[18] was based on a relatively small number of patients (n = 17),
we now based our analysis on a larger number of urine samples,
aiming to identify additional urinary peptides that are altered in
ADPKD and to assure an adequate number of individuals to
develop a robust biomarker score. We compared peptidome data
of 41 SUISSE ADPKD patients to 189 healthy controls (mean age
37615 years, 49% females). Compiled urinary proteomic patterns
of ADPKD and control patients are given in Figure 2. Statistical
comparison of cases and controls resulted in the identification of
657 peptides that were significantly different between the two
groups after adjustment for multiple testing. Of these, 209 could be
sequenced using high-resolution tandem mass spectrometry. Most
biomarker candidates were collagen fragments, possibly reflecting
substantial alteration in extracellular matrix (ECM) turnover. The
CE-MS characteristics of all differentially excreted peptides, their
regulation in ADPKD, and where applicable their sequence are
given in Table S1.
Based on these peptides we next established a support-vector-
machine (SVM)-based diagnostic score. Because the number of
potential biomarkers substantially exceeded the number of samples
in the study, we reduced the number of variables for the biomarker
model to the most consistently altered 142 peptides using a ‘‘take-
one-out’’ procedure in the total cross-validation of the training
data. Of these 142 peptides, 57 could be identified by means of
their peptide sequence (Table 2). The SVM-based model
combines the amplitude of all 142 markers for a given urine
sample into a score, which denotes the distance of that sample in a
142-dimensional space (every dimension representing the abun-
dance of one peptide) from a hyperplane that is designed to
separate the cases from controls. The parameters of the kernel
function for the 141-dimensional hyperplane were: cost (C) of 640
and kernel width (c) of 0.000003. Of these 142 markers, 23 had
been among the markers used in the previously published
ADPKD_38 model [18]. The SVM-based diagnostic model,
ADPKD_142, yielded an area under the receiver operator
characteristics curve (AUC) of 0.98 in the training cohort using
total take-one-out cross validation. Upon validation in the
independent CRISP cohort and 86 healthy controls, the model
achieved an AUC of 0.95 (95% confidence interval [CI] 0.92–
0.98), corresponding to a sensitivity of 84.4% and a specificity of
94.2% when using a predefined cutoff value that yielded optimal
sensitivity and specificity in the cross-validated training data
(Figure 3). A sensitivity analysis for potential center bias was
performed by applying the biomarker model to 27 SUISSE
ADPKD patients that were not used to generate the model,
yielding similar sensitivity (85.2%) as for the CRISP cohort.
Combination of CRISP patients and these 27 SUISSE ADPKD
patients to validate the model resulted in an overall sensitivity of
84.5%.
It has been suggested that in ADPKD, signaling pathways of
tubular cell injury and repair are inadequately activated [21].
Several acute kidney injury (AKI) and tubular injury markers, such
as NGAL [22] and KIM-1 [23,24] have been found to be elevated
in ADPKD. We therefore tested whether urinary proteomic
changes in ADPKD overlap with changes found in AKI. In fact, of
the 209 urinary peptides that were altered in ADPKD and have
been sequenced, 40 overlapped with peptide fragments that were
altered in acute kidney injury (AKI) patients [25] and in 17 of
these, one of the two (N- or C-terminal) cleavage sites was identical
to the AKI peptides: 13 collagen alpha-1(I), 1 albumin and 3
fibrinogen alpha fragments. When testing the ADPKD urines with
Urine Proteomics in ADPKD
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a CE-MS based biomarker model that has been developed to
detect AKI [25], 112 of all 292 ADPKD patients (38.4%) scored
positive, hence ADPKD patients show considerable signs of acute
kidney injury in their urinary peptidome. In contrast, when
applying the ADPKD_142 biomarker model to 38 urine samples
of 16 patients with AKI, none of the AKI urines scored positive for
ADPKD. This suggests that the ADPKD_142 biomarker model
contains additional markers that are specific for ADPKD vs. AKI.
To further evaluate the specificity of the ADPKD_142 model, we
tested a total of 481 patients suffering from a variety of non-cystic
renal and systemic diseases. Table 3 depicts the diagnostic groups
and their rates of false positive tests; overall specificity of the model
was 90.2%. Hence, the detected proteomic alterations are specific
for ADPKD and do not simply reflect renal damage. Finally,
combining all validation cohorts described above (i.e. all patients
that were not used for biomarker discovery: 224 CRISP patients,
27 SUISSE ADPKD patients, 86 healthy controls and 481
diseased controls, total n = 918), yielded an overall sensitivity and
specificity for ADPKD of 84.5% and 90.8%, respectively.
Table 1. Clinical characteristics of all CRISP and SUISSE
ADPKD study patients included in the proteomic analysis.
Cohort SUISSE ADPKD CRISP
N 68 224
Age 31.466.3 32.468.7
Sex (% female) 35.8 59.4
Hypertension (%) 70.8 61.6
eGFR 86.4615.5 89.1627.8
TKV 10236592 10786647
GenotypePKD1PKD2no detectable
mutation
not available 78.1%13.8%7.1%
eGFR, estimated glomerular filtration rate according to the MDRD study
formula; TKV, total kidney volume. Values are mean 6 SD unless otherwise
specified.
doi:10.1371/journal.pone.0053016.t001
Figure 1. Usage of samples and flow of information. A, Identification and validation of diagnostic biomarkers and biomarker models. 41 cases
of ADPKD were compared to 189 healthy controls, which resulted in the definition of 657 potential biomarkers. Of these, 142 were employed in an
SVM-driven biomarker model, ADPKD_142. All potential biomarkers and the biomarker model were evaluated in a test set of 310 blinded samples
that consisted of 224 samples from patients with ADPKD and 86 healthy controls. The ADPKD_142 model was further validated using additional
ADPKD samples from the SUISSE ADPKD study (n = 27) and using controls samples of patients with a variety of different renal and systemic diseases.
B, Identification and validation of biomarkers and biomarker model for disease severity. CE-MS data from 135 urine samples from patients with
ADPKD were correlated with height adjusted TKV (htTKV), resulting in the identification of 99 potential biomarkers associated with htTKV. Employing
linear combination, a biomarker models indicative of disease severity was established. This biomarker model was subsequently tested in a validation
set consisting of 153 ADPKD samples.
doi:10.1371/journal.pone.0053016.g001
Urine Proteomics in ADPKD
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The sensitivity and specificity of the diagnostic ultrasound
criteria depend on age and genotype, with sensitivity being
reduced in young patients and patients with PKD2 genotype [10].
The accuracy of the ADPKD_142 urinary biomarker model
exhibited a similar dependence on age and genotype (Table 4):
sensitivity was lower in young patients and in PKD2 genotype. In
the subgroup of patients with PKD1 genotype aged $20 years, the
model achieved a sensitivity of 91.9% and specificity of 93.0%.
Given the lack of prognostic markers for ADPKD, we next
tested whether the urinary proteome of ADPKD patients might
reflect disease severity and progression. Since the ADPKD_142
model was generated to distinguish ADPKD from healthy controls
with optimal accuracy, the diagnostic score is not expected to
correlate well with disease severity. Nevertheless, the
ADPKD_142 score correlated positively with total kidney volume
(TKV), height adjusted total kidney volume (htTKV) and absolute
annual TKV growth (ml per year) and negatively with GFR
(Table 5), but these correlations were weak. No correlation was
found with proteinuria and albuminuria. Since proteomic markers
that correlate highly with disease severity may have been excluded
from the diagnostic model due to their large variability within
ADPKD patients, we next tested the abundance of all 5352
urinary peptides detectable in ADPKD samples for correlation
with htTKV, which has been shown to be predictive of future
GFR decline and the development of CKD stage III [26]. The
analysis was done in a randomly chosen set of 134 patients and
validated in a set of 158 patients derived from both ADPKD
cohorts. 99 peptides showed a correlation (Spearman’s r) of
.0.25/,20.25 with htTKV (Table S2). Aiming at a classifier
that has superior value in comparison to a single biomarker, we
combined all 99 peptides in a linear model. When examining this
linear model, the correlation with htTKV was 0.590 (p,0.0001) in
the dataset that was used to identify these biomarkers and 0.415
(p,0.0001) in the independent validation set of 158 patients
(Figure 4). 43 of the 99 peptides could be identified by tandem
MS sequencing (Table 6). Clearly prominent is the negative
correlation of urinary collagen fragments with htTKV.
Discussion
This to the best of our knowledge the largest clinical proteomic
study reported so far. We analyzed urine samples from a total of
1,048 patients to characterize the urinary peptidomic pattern of
patients with relatively early disease stages of ADPKD. Compared
to our initial report [18], we have identified a large number of
additional peptides altered specifically in ADPKD and now
provide extensive validation in an independent, large and well
characterized ADPKD cohort (the CRISP cohort). Insights into
the pathways of the proteomic patterns are now becoming clearer
and specific proteomic markers appear to associate with disease
severity.
Sequencing of naturally occurring peptides still represents a
major challenge that frequently cannot be solved successfully
[27,28]. Nevertheless, we were able to identify over 200 peptides
associated with ADPKD in the training cohort. This vast number
of potential biomarkers is certainly to some degree representative
of the disease, enabling the generation of initial hypotheses linking
these biomarkers to pathophysiology. Interestingly, the proteomic
pattern of ADPKD showed some overlap with proteomic changes
during AKI, supporting the hypothesis that some of the pathways
driving cyst growth in ADPKD are mechanisms normally active
during acute kidney injury repair [21]. Even though individual
peptides demonstrated overlap between ADPKD and AKI, the
biomarker model was highly specific for ADPKD, as compared to
Figure 2. Compiled urinary protein profiles of ADPKD patients and healthy controls. Proteomic profiles for the training cohort (41
patients of the SUISSE ADPKD study vs. 189 controls, panel A) and the validation cohort (224 CRISP study samples vs. 86 controls, panel B) are
depicted separately. Normalized MS molecular weight (800–20,000 Da) in logarithmic scale is plotted against normalized CE migration time (18–
45 min). The mean signal intensity of polypeptides is given as peak height. In the lower panels, only the 142 biomarkers that were included in the
diagnostic biomarker model are depicted, and their amplitude is shown with 56 zoom compared to the upper panels.
doi:10.1371/journal.pone.0053016.g002
Urine Proteomics in ADPKD
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Table 2. Sequenced biomarkers used in the SVM-based model.
Training set Test set
Mass (Da)
CE-Time
(Min)
p-value
(BH)
Fold
change
p-value
(BH)
Fold
change Sequence Protein name
1613.82 23.99 1.13E-02 0.62963 4.57E-01 0.926 VGGGEQPPPAPAPRRE Xylosyltransferase 1
1580.88 23.87 1.18E-03 0.36086 2.45E-08 0.5575 IDQSRVLNLGPITR Uromodulin
1588.71 30.15 3.75E-07 7.16036 1.18E-07 1.5048 TGLSMDGGGSPKGDVDP Sodium/potassium-
transporting
ATPase subunit gamma
1715.98 20.93 1.58E-02 1.67142 5.18E-01 0.8368 VRYTKKVPQVSTPTL Serum albumin
3202.43 30.6 4.39E-05 12.30155 4.78E-03 1.3896 SSQGGSLPSEEKGHPQEESEESNVSMASLGE Secretogranin-1
1140.52 25.39 6.78E-06 0.05484 2.60E-02 0.6513 YNKYPDAVAT Osteopontin
3318.55 30.99 2.27E-03 0.55513 3.16E-02 0.6907 GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAV Metastasis-suppressor
KiSS-1
2445.1 28.24 2.67E-03 5.02023 1.99E-01 2.4947 mASDASHALEAALEQMDGIIAGTK Liprin-beta-2
1580.89 24.85 6.58E-03 3.37586 3.80E-10 3.101 LEIELQSLLATKHS Keratin, type I
cytoskeletal 25
1635.76 30.34 7.97E-05 3.39305 3.90E-01 0.9845 FIFPPSDEQLKSGTA Ig kappa chain C region
1142.56 21.89 2.78E-02 0.28994 3.93E-19 6.056 VSVNERVMPI Haptoglobin
1882.8 20.24 2.22E-03 2.05957 1.64E-04 1.3966 DEAGSEADHEGTHSTKRG Fibrinogen alpha chain
984.46 24.92 6.56E-05 6.15717 1.03E-12 2.2448 LAADDPEVR Ephrin-A1
2889.35 24.08 3.04E-02 3.77113 4.68E-02 1.2247 NGEAGSAGPpGppGLRGSpGSRGLPGADGRAG Collagen alpha-2(I) chain
3092.44 36.3 1.01E-02 0.44086 1.13E-03 0.6362 TGEVGAVGPpGFAGEKGPSGEAGTAGPpGTpGPQG Collagen alpha-2(I) chain
1173.53 37.49 3.30E-02 0.54615 8.89E-14 0.096 GPpGPpGPpGPVT Collagen alpha-1(XVII)
chain
1339.6 27.49 1.17E-02 0.67239 6.10E-11 0.2467 SpGERGETGPpGPA Collagen alpha-1(III)
chain
1324.59 28.7 6.56E-05 0.17368 1.38E-01 0.7682 TGPGGDKGDTGPpGP Collagen alpha-1(III)
chain
1623.73 24.12 5.64E-03 1.34979 2.30E-11 1.6404 DGApGKNGERGGpGGpGP Collagen alpha-1(III)
chain
1794.8 23.92 1.11E-03 1.60456 3.71E-17 2.0447 GNDGApGKNGERGGpGGpGP Collagen alpha-1(III)
chain
1989.88 32.44 1.81E-02 0.59974 1.12E-03 0.7419 SNGNpGPpGPSGSpGKDGPpGP Collagen alpha-1(III)
chain
2137.94 21.79 4.48E-03 1.69213 9.63E-09 1.7463 NGEpGGKGERGApGEKGEGGpPG Collagen alpha-1(III)
chain
2264.03 22.67 1.62E-02 2.63884 3.24E-02 1.436 KGDAGApGApGGKGDAGApGERGPpG Collagen alpha-1(III)
chain
2525.2 27.74 2.14E-02 0.45892 9.41E-06 0.5216 LRGGAGPpGPEGGKGAAGPpGPpGAAGTpG Collagen alpha-1(III)
chain
2564.15 22.98 1.11E-03 2.13239 6.52E-08 1.8085 GApGQNGEpGGKGERGApGEKGEGGPpG Collagen alpha-1(III)
chain
2580.14 22.98 8.95E-03 1.83953 3.43E-12 2.0512 GApGQNGEpGGKGERGApGEkGEGGPpG Collagen alpha-1(III)
chain
2823.33 29.12 3.19E-02 0.48201 1.08E-03 0.6638 LRGGAGpPGPEGGKGAAGpPGppGAAGTPGLQG Collagen alpha-1(III)
chain
2825.27 24.49 3.60E-04 1.44938 1.53E-12 1.7677 ERGEAGIpGVpGAKGEDGKDGSpGEpGANG Collagen alpha-1(III)
chain
3255.49 30.78 1.71E-03 3.79654 2.60E-02 1.7139 NTGApGSpGVSGPKGDAGQpGEKGSpGAQGPPGAPGP Collagen alpha-1(III)
chain
3258.46 22.92 6.22E-03 1.88038 1.05E-01 1.5147 ENGKPGEpGpKGDAGApGApGGKGDAGApGERGpPG Collagen alpha-1(III)
chain
911.43 25.88 1.42E-04 0.38645 1.33E-09 0.3484 DGKTGPpGPA Collagen alpha-1(I) chain
1050.48 26.92 5.68E-03 0.54258 1.73E-11 0.3488 MGPRGPpGPpG Collagen alpha-1(I) chain
1080.5 25.69 4.18E-03 0.35998 7.44E-02 0.4841 ApGDRGEpGPP Collagen alpha-1(I) chain
1096.48 26.08 3.79E-04 0.54362 4.00E-10 0.6097 ApGDRGEpGpP Collagen alpha-1(I) chain
1143.52 36.97 6.47E-04 0.40166 0.00E+00 0.1049 GLPGPpGPpGPpG Collagen alpha-1(I) chain
Urine Proteomics in ADPKD
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other renal diseases, including AKI, and the overall pattern of
peptidomic alterations confers specificity for ADPKD, hence
underscoring the advantage of the SVM-based approach to
integrate a high number of individual markers with low specificity
into a highly specific multidimensional model.
We observed the most prominent proteomic changes in
collagen-derived peptides, which represent the majority of the
identified biomarkers for ADPKD in this study. The formation of
cysts mandates reorganisation of ECM and the increase in tissue
collagen required for cyst growth may result in reductions in
collagen degradation products. In a recent manuscript, regulation
of collagen expression by PKD1 and PKD2 was described,
arguing for a negative feedback provided by the polycystin
proteins [29]. This is exactly what we observed: a large number of
urinary collagen fragments are altered in ADPKD and most of
these (about 80%) are in fact down-regulated. In addition, with
one exception, all collagen fragments that significantly associated
with htTKV are negatively correlated: increasing htTKV (hence
severity of disease) is reflected by reduced excretion of specific
urinary collagen fragments. We also observed consistent upregula-
tion of peptide fragments from a specific region of fibrinogen alpha
chain and of keratin in ADPKD. While the pathophysiological
relevance of these findings are not obvious yet, over-expression of
genes encoding keratin 19 and fibronectin has been associated
with accelerated renal cystogenesis in a mouse PKD model [30]
and upregulation of keratin 19 and 2 was associated with ADPKD
in a gene profiling study [31]. We further observed consistent
downregulation of c-terminal fragments of uromodulin associated
with ADPKD, which may be a result of reduced uromodulin
degradation. Uromodulin staining was reported to be clearly
present in cysts of ADPKD patients [32], indicating reduced
degradation, in line with our findings. Osteopontin was reported
to be increased in animal models of ADPKD [33] and the reduced
excretion of an osteopontin fragment in urine in this study may
indicate reduced degradation leading to tissue accumulation.
From a pathophysiological point of view, it is remarkable that a
model derived from a cohort primarily consisting of PKD1
patients (although not genotyped, most patients of the SUISSE
ADPKD study are expected to have the PKD1 genotype) still
positively diagnosed most (77.4%) of the PKD2 patients. This
suggest that the majority of biomarkers identified and utilized in
the classifier reflect ongoing tissue remodeling that occurs in
ADPKD independent of genotype. Importantly, the model did not
merely reflect any kind of renal damage, given its remarkable
specificity for ADPKD vs. other renal diseases. The direct
comparison of PKD1 and PKD2 patients as well as patients with
other cystic renal diseases may allow the identification of
genotype-specific markers that might be more closely linked to
early disease-initiating processes. However, such studies will
Table 2. Cont.
Training set Test set
Mass (Da)
CE-Time
(Min)
p-value
(BH)
Fold
change
p-value
(BH)
Fold
change Sequence Protein name
1157.54 37.44 2.34E-02 0.67572 0.00E+00 0.1177 GPPGPpGppGPPS Collagen alpha-1(I) chain
1247.52 22 5.32E-04 1.99799 3.77E-12 2.3055 DKGETGEQGDRG Collagen alpha-1(I) chain
1297.58 27.36 4.84E-03 0.51815 6.18E-03 0.6989 SpGSpGPDGKTGPp Collagen alpha-1(I) chain
1458.63 27.94 2.96E-04 0.31301 2.66E-04 0.3525 SpGENGApGQmGPRG Collagen alpha-1(I) chain
1469.67 23.69 3.04E-02 1.35379 1.50E-12 1.9438 DGQPGAKGEpGDAGAK Collagen alpha-1(I) chain
1491.74 39.83 1.45E-05 0.31846 2.70E-10 0.3511 VGPpGpPGPPGPPGPPS Collagen alpha-1(I) chain
1680.75 30.03 3.60E-04 1.67867 1.02E-04 1.3047 TGSpGSpGPDGKTGPpGPA Collagen alpha-1(I) chain
1684.67 31.75 8.38E-04 0.69637 0.00E+00 0.2026 EpGSpGENGApGQMGPR Collagen alpha-1(I) chain
2014.9 21.91 1.42E-04 2.00095 5.82E-23 2.384 EGSpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain
2128.98 26.97 8.32E-05 0.28973 2.51E-02 0.5359 DGKTGpPGPAGQDGRPGPpGppG Collagen alpha-1(I) chain
2210.95 33.61 3.36E-02 1.52269 2.69E-09 1.4605 NGApGNDGAKGDAGApGApGSQGApG Collagen alpha-1(I) chain
2407.09 27.67 1.44E-03 0.63697 5.06E-02 0.9479 LDGAKGDAGPAGPKGEpGSpGENGApG Collagen alpha-1(I) chain
2471.16 34.77 1.18E-02 0.50314 1.01E-09 0.5201 TGPIGPpGPAGApGDKGESGPSGPAGPTG Collagen alpha-1(I) chain
2639.29 21.42 5.69E-03 0.41876 4.26E-01 0.8895 KEGGKGPRGETGPAGRpGEVGpPGPpGP Collagen alpha-1(I) chain
2713.23 29.22 1.37E-02 0.42363 7.24E-01 0.6891 PpGADGQpGAKGEpGDAGAKGDAGPpGPAGP Collagen alpha-1(I) chain
2767.32 21.67 2.51E-02 0.51467 9.78E-02 0.7323 KEGGKGPRGETGPAGRpGEVGpPGPpGPAG Collagen alpha-1(I) chain
2942.3 22.23 3.52E-03 1.46282 2.46E-04 1.3039 ESGREGApGAEGSpGRDGSpGAKGDRGETGP Collagen alpha-1(I) chain
3011.39 29.75 2.63E-04 0.59664 1.18E-11 0.5752 LTGSpGSpGpDGKTGPPGPAGQDGRPGPpGppG Collagen alpha-1(I) chain
3264.56 25.75 4.90E-02 0.66949 2.30E-04 0.7512 AAGEPGkAGERGVpGPpGAVGPAGKDGEAGAQGPPGP Collagen alpha-1(I) chain
3295.53 25.45 5.57E-05 0.2414 1.60E-04 0.3386 DRGETGPAGPpGApGAPGAPGPVGpAGKSGDRGETGP Collagen alpha-1(I) chain
1128.39 33.59 2.29E-03 2.54104 4.36E-08 0.4147 DFDDFNLED CD99 antigen-like
protein 2
2256.97 33.55 6.15E-03 0.49781 3.08E-03 0.8933 ATNSTAGYSIYGVGSmSRYEQ Calsyntenin-2
Given are molecular mass (in Da), normalized migration time (in min), adjusted p-value (Benjamini and Hochberg) and regulation factor (mean signal intensity of ADPKD
samples divided by mean signal intensity of control samples) for training- and test set, amino acid sequence (modified amino acids: p = hydroxyproline;
k = hydroxylysine; m= oxidized methionine) and parental protein name.
doi:10.1371/journal.pone.0053016.t002
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require substantially larger cohorts, as these likely more subtle
changes mandate larger number of samples to be included.
In the majority of cases, the diagnosis of ADPKD is relatively
straight forward using ultrasound imaging. Renal ultrasound
reaches a very high accuracy in patients with PKD1 genotype aged
.30 years [10], and is therefore unlikely to be outreached by
alternate diagnostic methods. However, imaging-based diagnosis
of ADPKD has limited sensitivity in young patients, particularly
those with a PKD2 genotype [10]. We therefore wondered
whether urinary proteomics might be useful for ADPKD diagnosis
in this patient group. However, similar to the accuracy of
ultrasound diagnostic criteria [10] the diagnostic biomarker model
exhibited a reduced sensitivity in young patients and in patients
with PKD2 genotype and a slightly reduced specificity in older
patients. Since for all patients in the validation cohort (the CRISP
cohort) ADPKD diagnosis was based on ultrasound imaging, the
sensitivity of our proteomic biomarker model might be somewhat
lower when applied to an at-risk population, including patients
very early in the course with genetically proven disease but
negative imaging results. Hence, despite the very high overall
accuracy of our diagnostic biomarker model, it will need further
refinement before providing benefit over ultrasound based
diagnosis in clinical practice. Urine proteome analysis of very
young, mutation positive ADPKD patients with no detectable cysts
yet might allow the identification of very early and subtle
proteomic alterations that may have gone undetected in our study.
A major challenge in the management of patients with ADPKD
is to predict prognosis. Even within a family the disease course
exhibits a high variability [4]. Disease prediction will gain further
importance with the development of specific treatment options.
Such treatments will most likely need to be started early during
disease course to affect outcome, before the majority of
functioning kidney tissue has been replaced by cysts. One focus
of our studies was therefore the evaluation of urine proteome
utility in predicting severity and progression of ADPKD. We
anticipated that the diagnostic biomarker score would not exhibit
strong associations with disease severity and progression, since it
was designed to discriminate ADPKD patients from controls with
high accuracy, but not to detect differences among ADPKD
patients. Urinary peptides with highly variable excretion among
Figure 3. ROC curve with 95% CI for the differentiation of
ADPKD patients from healthy controls by the biomarker model
ADPKD_142 applied to the CRISP validation cohort and 86
healthy individuals.
doi:10.1371/journal.pone.0053016.g003
Table 3. Demographic characteristics and numbers of false positive results in controls with other renal and non-renal diseases.
Diagnosis N
Number of false positive
results Age (mean ± SD) Sex (% female)
FSGS 31 2 38.8611.6 35.4
IgAN 70 9 36.7612.8 32.9
MN 46 2 44.667.9 19.6
MCD 29 2 35.6612.3 41.4
DNP 83 8 48.666.7 26.5
AKI 16 0 61.7613.3 50.0
Fanconi 11 0 13.469.4 36.4
Renal diseases, others 10 0 48.967.7 40.0
DM type 1 without DNP 42 7 40.9610.3 45.2
DM type 2 without DNP 12 0 49.469.1 25.0
SLE 45 6 38.768.8 71.1
Vasculitis 12 1 42.6615.2 41.7
Bladder cancer 22 1 51.166.2 9.1
Liver transplantation 6 0 45.7613.2 0
Stem cell transplantation 46 9 50.6613.5 37.0
All diseased controls combined 481 47 42.7611.7 35.6
FSGS, focal and segmental glomerulosclerosis; IgAN, IgA nephropathy; MN, membranous nephropathy; MCD, minimal change disease; DNP, diabetic nephropathy; AKI,
acute kidney injury; DM, diabetes mellitus; SLE, systemic lupus erythematosus.
doi:10.1371/journal.pone.0053016.t003
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ADPKD patients that might correlate with disease severity may
have been excluded from the diagnostic model since they are less
useful to differentiate ADPKD versus controls. Nevertheless,
ADPKD_142 correlated with several measures of disease severity
and progression, including the annual TKV growth, although
these correlations were moderate. We therefore developed a linear
model that was specifically designed to correlate with ADPKD
severity. A shortcoming of such efforts is the absence of a clear
measure for disease progression. Future development of ESRD
would likely be the best variable, but this was not available for
most patients, as it would require an unfeasibly long observation
time for patients with early disease. We therefore chose as a
surrogate marker htTKV, which has recently been shown to be a
strong predictor of the development of KDOQI CKD Stage 3 and
4 within 8 years in ADPKD patients [26]. A linear model to
predict htTKV achieved a high accuracy. This clearly shows, that
a subset of proteomic markers different from the diagnostic
peptides reflect disease severity. The CRISP and SUISSE studies
continue to follow-up data on these patients, including GFR,
which will, in the future, serve to validate the current model as a
predictive tool and may allow the derivation of a biomarker model
that directly predicts TKV growth and GFR decline over time.
Several potential urinary and plasma biomarkers for ADPKD
have recently been reported, including NGAL [22], MCP-1
[24,34], KIM-1 [23,24], CD-14 and copeptin [35]. These
markers, however, are all unspecific for ADPKD and mostly
show considerable overlap with healthy controls. Copeptin, CD14
and NGAL correlated with disease severity in the initial reports,
however, in the case of NGAL, this could not be confirmed in a
subsequent study [36]. The other markers mostly still lack
independent validation. Gronwald et al. [37] recently used a
metabolomic approach based on NMR spectroscopy of urine and,
similar to our approach, combined multiple markers through an
SVM algorithm. Although lacking validation in an independent
cohort, their model achieved an AUC of 0.91 for the discrimi-
nation of ADPKD from normal controls upon nested cross-
validation. Like our study, this report demonstrates the potential
usefulness of multidimensional profiling of biological fluids to
detect biomarker patterns rather than individual markers. On the
other hand, the application of ‘‘omic’’ approaches to biomarker
discovery is inherently susceptible to overestimating the signifi-
cance of the findings due to multiple testing, and to model over-
fitting when combining biomarkers to classifiers. We have
therefore extensively validated our proteomic biomarker model
for ADPKD by testing it in the CRISP cohort, a large prospective
ongoing ADPKD registry where information on the PKD
genotype was available, and in a large group of healthy and
diseased controls.
In summary, our study demonstrates that the urine proteome is
profoundly altered in young ADPKD patients and that proteomic
profiling can be used to derive diagnostic and prognostic models
Table 4. Sensitivity and specificity of the ADPKD biomarker model according to age and genotype subgroup and using three
different diagnostic cut off values.
all patients age,30 age.30 PKD1 PKD2
cut off sens spec sens spec sens spec sens spec sens spec
20.169 0.844 0.942 0.720 0.975 0.920 0.913 0.863 0.942 0.774 0.942
20.250 0.875 0.907 0.768 0.950 0.937 0.870 0.891 0.907 0.806 0.907
20.400 0.906 0.895 0.817 0.925 0.958 0.870 0.914 0.895 0.903 0.895
doi:10.1371/journal.pone.0053016.t004
Figure 4. Scatter plots for correlation between classification scores of linear model for disease progression and the height adjusted
TKV: Depicted are also the regression line and 95% confidences. In A training set data are showed and in B test set data.
doi:10.1371/journal.pone.0053016.g004
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for ADPKD. Further refinement of the presented models will be
necessary for future clinical application.
Methods
Patients and Procedures
All analyzed urines were morning spot urine samples drawn
after the first morning void. ADPKD samples were from baseline
visits of two clinical studies: the SUISSE ADPKD study (68 urine
samples) and the CRISP cohort (224 urine samples; since all urine
samples from the SUISSE ADPKD study were from Caucasian
patients, we excluded African American CRISP participants from
analysis). Both studies were described in detail elsewhere
[38,39,40,41,42]. Shortly, the SUISSE ADPKD study was an
open-label randomized, controlled trial evaluating the effect of
sirolimus treatment on kidney volume growth in ADPKD patients
aged 18 to 40 years with a creatinine clearance $70 ml/min.
Patients underwent magnetic resonance imaging (MRI) of their
kidneys at 6 months intervals and kidney volumes were
determined by a manual segmentation method. The CRISP study
was an observational longitudinal study including ADPKD
patients aged 16 to 45 years with a creatinine clearance
$70 ml/min. All patients underwent MRI of their kidneys at
annual intervals and kidney volumes were determined by
stereology. The total follow up time was 3 years. TKV growth
rate was calculated for all patients from both studies as absolute
progression rate in ml per year, and as relative growth rate in
percent per year by regressing either TKV or log-transformed
TKV over time. From the SUISSE ADPKD study, only patients
which did not receive sirolimus treatment with at least 4 sequential
MRI kidney volume measurements available (N=48) were used to
calculate TKV progression. We used urine samples from the first
41 patients that had been enrolled in the SUISSE ADPKD study
and that have been previously analyzed in our first report on urine
proteomics in ADPKD [18] as training samples for the refined
diagnostic biomarker model and the remaining SUISSE ADPKD
urine samples as a second validation cohort (in addition to the
CRISP cohort, to test for center bias). Control urine samples have
been previously collected as part of several clinical studies (refs
[13,18,25,43,44,45,46,47] and as yet unpublished studies). Demo-
graphic characteristics of controls with other renal and non-renal
diseases are given in Table 3. Healthy control urine samples were
collected from volunteers that did not report any history of renal
or chronic extrarenal diseases. Mean age of healthy controls was
37615 years, 49% were females. Out of the healthy control urine
samples we randomly chose 2/3 of all samples for biomarker
identification and model generation and used the remaining
samples as part of the independent validation cohort. Informed
consent was obtained from all patients and healthy controls after
local ethics committee approval. These studies were performed in
accordance with the Helsinki Declaration.
Sample preparation and CE-MS analysis
All urine samples for CE-MS analyses were stored at 280uC
until analysis and underwent a maximum of 2 freeze/thaw cycles.
CE-MS analysis was performed exactly as described previously
[48]. Briefly, an aliquot was thawed immediately before use, 1:1
diluted with 2 M urea, 10 mM NH4OH, 0.02% SDS, filtered
using Centrisart ultracentrifugation filter devices (20 kDa
MWCO; Sartorius, Goettingen, Germany) to remove higher
molecular weight proteins, desalted on a PD-10 desalting column
(Amersham Bioscience, Uppsala, Sweden), equilibrated in 0.01%
NH4OH in HPLC-grade H2O, lyophilized, stored at 4uC, and
resuspended in HPLC-grade H2O shortly before CE-MS analysis.
CE-MS analysis was performed using a P/ACE MDQ capillary
electrophoresis system (Beckman Coulter, Fullerton, USA) on-line
coupled to a Micro-TOF MS (Bruker Daltonic, Bremen,
Germany) as described [48].
Proteomic data processing and cluster analysis
MosaiquesVisu software [49] was used to deconvolve mass
spectral ion peaks representing identical molecules at different
charge states into single masses. Migration time and ion signal
intensity were normalized using internal polypeptide standards
[50] that are unaffected by any disease state studied to date [51].
All detected polypeptides were deposited in a Microsoft SQL
database, allowing comparison of multiple samples (patient
groups).
Statistical methods, definition of biomarkers and sample
classification
Statistical calculations were carried out in MedCalc version
8.1.1.0 (MedCalc Software, Mariakerke, Belgium, http://www.
medcalc.be). Confidence intervals (95% CI) were estimated based
on exact binomial calculations. The reported unadjusted p-values
were calculated using the natural logarithm-transformed intensities
of the CE-MS spectra and the Gaussian approximation to the t-
distribution. Statistical adjustment for multiple testing was
performed by the method described by Benjamini and Hochberg
[52].
Disease-specific polypeptide patterns were generated using
SVM based MosaCluster software [53]. The algorithm has been
recently described [54]. Briefly, MosaCluster uses Gaussian basis
radial functions (RBF) as kernel function to map the data into the
high dimensional feature space, where the separating hyperplane
can be defined. Ideally, the hyperplane should separate the
subjects into two non-overlapping groups, what is often impossible
in reality. The accuracy of an SVM model is largely dependent of
the selection of model parameters like cost (C) and kernel width (c).
C controls the trade off between allowing training errors and
forcing rigid margins and c controls the width of SVM kernel. To
optimize this parameters gird search method was used: the model
was evaluated via cross validation at many points within the gird
for each parameter to destine the best possible parameter
combination. The calculated scores, based on the amplitude of a
set of markers, denote the distance of that sample in an n-
dimensional space (every dimension representing the amplitude of
one marker and n being the number of markers combined to a
Table 5. Correlation of the biomarker score with clinical
markers of disease severity and progression.
Clinical parameter Spearman’s rho p-value
TKV 0.308 ,0.001
TKV/height 0.310 ,0.001
TKV change (ml per year) 0.225 0.001
TKV change (% per year) 0.098 0.134
MDRD GFR 20.284 ,0.001
iothalamate GFR 20.188 0.005
Proteinuria 20.029 0.698
Albuminuria 0.060 0.389
TKV, total kidney volume.
doi:10.1371/journal.pone.0053016.t005
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Table 6. Identified 54 biomarkers of the 99 biomarkers that correlated with height adjusted TKV.
Mass (Da) CE-Time (min) Spearman’s rho p-values Sequence Protein name
840.41 23.17 20.258 1.76E-06 KGDTGPpGP Collagen alpha-1(III) chain
858.39 23.24 20.273 9.08E-06 SpGEAGRpG Collagen alpha-1(I) chain
935.45 23.68 20.253 2.83E-05 GRpGPpGPpG Collagen alpha-1(I) chain
1040.48 25.05 20.312 7.92E-05 SpGPDGKTGPp Collagen alpha-1(I) chain
1050.48 26.92 20.280 1.34E-04 MGPRGPpGPpG Collagen alpha-1(I) chain
1058.48 24.89 0.324 1.46E-04 TISRLEPED Ig kappa chain V-III region NG9
1096.48 26.08 20.325 1.66E-04 ApGDRGEpGpP Collagen alpha-1(I) chain
1097.50 21.00 0.301 1.67E-04 AHVDDmPNAL Hemoglobin subunit alpha
1114.49 25.55 20.288 2.09E-04 SpGERGETGPp Collagen alpha-1(III) chain
1189.60 21.18 0.271 2.60E-04 YGRAPQLRET Alpha-1-microglobulin
1223.57 19.39 0.287 2.66E-04 DHEGTHSTKRG Fibrinogen alpha chain
1251.62 22.53 20.267 3.10E-04 DGVPGKDGPRGPT Collagen alpha-1(III) chain
1257.64 19.92 0.346 3.15E-04 TISEKTSDQIH Antithrombin-III
1265.59 27.09 20.281 3.33E-04 SpGPDGKTGPpGPA Collagen alpha-1(I) chain
1268.57 27.25 0.321 3.66E-04 SpGERGETGPpGP Collagen alpha-1(III) chain
1378.61 28.82 20.373 7.31E-04 ApGEDGRpGPpGPQ Collagen alpha-1(II) chain
1430.65 29.24 0.267 9.27E-04 DSEETRAAAPQAW Drebrin
1447.70 19.47 20.254 9.49E-04 DTDRFSSHVGGTLG Inter-alpha-trypsin inhibitor heavy chain H4
1467.66 29.07 0.275 9.97E-04 SpGSpGPDGKTGPpGp Collagen alpha-1(I) chain
1525.67 30.39 20.316 1.04E-03 YKTTPPVLDSDGSF Ig gamma-1 chain C region
1591.74 30.39 0.307 1.07E-03 IGPpGPAGApGDKGESGP Collagen alpha-1(I) chain
1630.74 20.65 20.266 1.25E-03 EGSpGRDGSpGAKGDRG Collagen alpha-1(I) chain
1636.86 23.18 0.313 1.36E-03 LSALEEYTKKLNTQ Apolipoprotein A-I
1680.75 30.03 20.257 1.46E-03 TGSpGSpGPDGKTGPpGPA Collagen alpha-1(I) chain
1692.80 30.89 20.277 1.48E-03 PpGEAGKpGEQGVPGDLG Collagen alpha-1(I) chain
1734.79 23.58 20.282 1.57E-03 GppGPPGKNGDDGEAGKPG Collagen alpha-1(I) chain
1767.00 24.11 0.321 1.59E-03 SVIDQSRVLNLGPITR Uromodulin
1796.75 29.45 20.272 1.60E-03 GEpGApGSKGDTGAKGEpGP Collagen alpha-1(I) chain
1837.80 30.56 20.274 1.63E-03 AVAHVDDMPNALSALSDL Hemoglobin subunit alpha
1847.89 43.67 20.253 1.65E-03 DAGPVGPpGPpGPpGPPGPPS Collagen alpha-1(I) chain
1859.83 24.41 20.266 1.68E-03 NSGEpGApGSKGDTGAKGEp Collagen alpha-1(I) chain
1860.83 21.40 20.284 1.84E-03 EGSpGRDGSpGAKGDRGET Collagen alpha-1(I) chain
1916.85 24.63 20.258 1.94E-03 GNSGEPGApGSkGDTGAKGEp Collagen alpha-1(I) chain
1954.97 25.36 0.333 2.25E-03 SHTSDSDVPSGVTEVVVKL Clusterin
2042.07 25.14 0.295 2.27E-03 EAIPMSIPPEVKFNKPFV Alpha-1-antitrypsin
2059.01 33.08 0.281 2.31E-03 ELTETGVEAAAASAISVARTL Plasma protease C1 inhibitor
2080.94 20.20 20.266 2.36E-03 DAHKSEVAHRFKDLGEEN Serum albumin
2389.24 22.40 0.260 2.63E-03 MIEQNTKSPLFMGKVVNPTQK Alpha-1-antitrypsin
2391.20 22.62 0.262 2.70E-03 AAHLPAEFTPAVHASLDKFLASV Hemoglobin subunit alpha
2405.22 22.47 0.273 2.70E-03 MIEQNTKSPLFmGKVVNPTQK Alpha-1-antitrypsin
3092.46 31.25 20.363 2.93E-03 ADGQPGAkGEPGDAGAKG-
DAGPPGPAGpAGpPGPIG
Collagen alpha-1(I) chain
3108.45 31.28 20.312 2.95E-03 ADGQpGAKGEpGDAGAKGD-
AGpPGPAGPAGPPGpIG
Collagen alpha-1(I) chain
3149.46 31.25 20.259 3.00E-03 GADGQPGAKGEpGDAGAKGDA-
GPpGPAGpAGPPGPIG
Collagen alpha-1(I) chain
Given are molecular mass (in Da), normalized migration time (in min), the Spearman’s coefficient of rank correlation and the significance level (p-values). In addition,
amino acid sequence (modified amino acids: p = hydroxyproline; k = hydroxylysine; m= oxidized methionine) and parent protein names are given.
doi:10.1371/journal.pone.0053016.t006
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model) from an (n-1)-dimensional hyperplane that is designed to
separate the cases from controls.
Sequencing of polypeptides
The urine samples were analysed on a Dionex Ultimate 3000
RSLS nano flow system (Dionex, Camberly UK). The samples
(5 ml) were loaded onto a Dionex 100 mm62 cm65 mm C18 nano
trap column at a flow rate of 5 ml/min in 0.1% formic acid and
acetonitrile (98:2). Once loaded onto the trap column the sample
was washed off into an Acclaim PepMap C18 nano column
75 mm615 cm, at a flowrate of 0.3 ml/min. The trap and nano
flow column were maintained at 35 C. The samples were eluted
with a gradient of solvent A: 0.1% formic acid versus solvent B:
acetonitrile starting at 5% B rising to 50% B over 100 min. The
eluant from the column was directed to a Proxeon nano spray ESI
source (Thermo Fisher Hemel UK) operating in positive ion mode
then into an Orbitrap Velos FTMS. The ionisation voltage was
2.5 kV and the capillary temperature was 200uC. The mass
spectrometer was operated in MS/MS mode scanning from 380 to
2000 amu. The top 10 multiply charged ions were selected from
each full scan for MS/MS analysis, the fragmentation method was
HCD at 35% collision energy. The ions were selected for MS2
using a data dependent method with a repeat count of 1 and
repeat and exclusion time of 15 s. Precursor ions with a charge
state of 1 were rejected. The resolution of ions in MS1 was 60,000
and 7,500 for HCD MS2. Data files were searched against the IPI
human non-redundant database using the Open Mass Spectrom-
etry Search Algorithm (OMSSA, http://pubchem.ncbi.nlm.nih.
gov/omssa) and Proteome Discoverer (Thermo), without any
enzyme specificity. No fixed modification was selected, and
oxidation of methionine and proline were set as variable
modifications. Mass error window of 10 ppm and 0.05 Da were
allowed for MS and MS/MS, respectively. For further validation
of obtained peptide identifications, the strict correlation between
peptide charge at pH of 2 and CE-migration time was utilized to
minimize false-positive identification rates [55]. Calculated CE-
migration time of the sequence candidate based on its peptide
sequence was compared to the experimental migration time.
Accepted were peptides which were found with both search
algorithms (OMSSA and Proteome Discoverer), and a CE-
migration time deviation below 61 min.
Supporting Information
Table S1 Characteristics of the 657 peptides with
altered excretion in ADPKD. The peptide identification
number in the dataset (Peptid ID), molecular mass (in Da) and
normalized migration time (in min) are shown along with the
AUC-values, p-values adjusted according to Benjamini-Hochberg
and the regulation factor for the comparison of cases with controls
for both, the training and the validation cohort. In addition, amino
acid sequence (modified amino acids: p = hydroxyproline; k = hy-
droxylysine; m=oxidized methionine), parent protein name with
the position of the first (start) and last (stop) amino acid of the
identified peptide within the parent protein, the SwissProt/
TrEMBLEentry numbers and accession numbers are given. The
first 142 peptides were employed in the diagnostic SVM model.
(PDF)
Table S2 Characteristics of the 99 biomarkers corre-
lated with height adjusted TKV. Shown are the peptide
identification number in the dataset (Peptid ID), molecular mass
(in Da) and normalized migration time (in min). Given are the
Sperman’s coefficient of rank correlation and the significance level
(p-values). In addition, amino acid sequence (modified amino
acids: p = hydroxyproline; k = hydroxylysine; m=oxidized methi-
onine), parent protein name with the position of the first (start) and
last (stop) amino acid, the SwissProt/TrEMBLEentry numbers
and accession numbers are given.
(PDF)
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